Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cf-pharmtech-inc-class-h" target="_blank" data-smartkarma-citation="entities:48966:1" rel="noopener">CF PharmTech (2652 HK)</a> intends to place 22M H Shares at the price of HK$13.82 per share. The placing price represents a discount of ~12% to the undisturbed closing price.</li>
<li>The company intends to apply the net proceeds mainly for clinical and pre-clinical development of its innovative drug candidates and development of its complex inhalation formulation products globally.</li>
<li>On October 8, 2025, CF PharmTech got listed on the HK Stock Exchange. The net proceeds from the Global Offering amounted to ~HK$525M, of which HK$129M had been utilized.</li>
</ul>



CF PharmTech (2652 HK) intends to place 22M H Shares at the price of HK$13.82 per share. The placing price represents a discount of ~12% to the undisturbed closing price.
The company intends to apply the net proceeds mainly for clinical and pre-clinical development of its innovative drug candidates and development of its complex inhalation formulation products globally.
On October 8, 2025, CF PharmTech got listed on the HK Stock Exchange. The net proceeds from the Global Offering amounted to ~HK$525M, of which HK$129M had been utilized.


CF PharmTech (2652 HK) Placement: Raising Fund to Feed R&D Amid Unutilized IPO Proceeds